Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension, Menopause, Premature, Menopause, Blood Pressure
Interventions: Microneurography to measure muscle sympathetic nerve activity (MSNA), Baroreflex sensitivity testing, Sympathoexcitatory Maneuvers, Blood tests; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Glaucoma
Interventions: NT-501 ECT implant, Sham; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: GDM, Preterm Preeclampsia, Preeclampsia, Fetal Growth Restriction (FGR), Pregnancy Complications
Interventions: None (this is an observational study with no intervention); Other
Lead sponsor: Medicines360; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 5,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Bridgeport, Connecticut • New Haven, Connecticut • Baton Rouge, Louisiana + 2 more

Conditions: Pulmonary Arterial Hypertension
Interventions: iron supplement; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension, Overweight or Obesity
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 28
States / cities: Phoenix, Arizona • Covina, California • Northridge, California + 24 more

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution 0.02%, Placebo Comparator; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Rochester, Minnesota • Durham, North Carolina

Conditions: Diabetes Mellitus, Hypertension, Coronary Artery Disease, Atrial Fibrillation, Stroke
Interventions: PHCVRS Intervention, Personal Health Record; Other
Lead sponsor: Korey Kennelty; Other
Eligibility: 50 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 12
States / cities: Akron, Iowa • Belmond, Iowa • Cedar Rapids, Iowa + 9 more

Conditions: Glaucoma, Retinal Pathology
Interventions: Not listed
Lead sponsor: Mid-Atlantic Glaucoma Experts; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension, Prehypertension
Interventions: MB-BP Intervention, Enhanced Usual Care Control; Behavioral · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Glaucoma
Interventions: Brimonidine Tartrate Ophthalmic 0.025%; Drug
Lead sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hypertension
Interventions: Web-Based Intervention; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Hypertension in Pregnancy
Interventions: Mindfulness Training; Behavioral
Lead sponsor: Lifespan; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Portal Hypertension Related to Cirrhosis
Interventions: Carvedilol, Variceal band ligation; Drug · Procedure
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Blood High Pressure
Interventions: DASH diet, Low Na diet, High Na diet, Usual Diet; Other
Lead sponsor: Purdue University; Other
Eligibility: 11 Years to 15 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Indianapolis, Indiana • West Lafayette, Indiana

Conditions: Pulmonary Arterial Hypertension
Interventions: Riociguat (Adempas, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 38 more

Conditions: Hypertension
Interventions: losartan potassium; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Hypertension
Interventions: ALTA; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Preeclampsia, Pregnancy Induced Hypertension, Gestational Hypertension, Chronic Hypertension, Superimposed Preeclampsia
Interventions: labetalol (seizure prevention), MgSO4 (seizure prevention); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 15 Years to 60 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: CHF, Renal Disease, Hypertension
Interventions: Not listed
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma
Interventions: bevacizumab, balanced salt solution; Drug · Other
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Ocular Hypertension
Interventions: latanoprost 0.005% eye drops and brimonidine 0.1% eye drops, latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes, Hypertension
Interventions: Diabetes Group Management Visits; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Durham, North Carolina • Richmond, Virginia

Conditions: Glaucoma
Interventions: Pilocarpine, Prednisolone, Ofloxacin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 30 Years to 100 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Sarcopenia, High Blood Pressure, Hypertension
Interventions: progressive resistance training; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 60 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study

Oral Iron Supplementation in Pulmonary Hypertension

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care

Ability of Patients With Low Vision to Properly Instill Eye Drops

Mindfulness-Based Blood Pressure Reduction: Stage 2a RCT

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Individually Tailored Web-Based Program to Improve Blood Pressure Control

Prenatal Mindfulness & Hypertension Study

Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding

DASH-Sodium Trial in Adolescents

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions

Bridging the Evidence-to-practice Gap

Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial

Validation of a Sensor for Non-Invasive Measurements

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Can Group Visits Improve Outcomes of Veterans With Diabetes

Pilocarpine Use After Kahook Goniotomy

The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia